Putrescine topical barrier formulation

Abstract

The present invention describes stable topical barrier compositions comprising primary polyamines and uses thereof for protecting the skin from external stressors, for improving skin's moisture and fort stimulating healing of the skin. These compositions may be used in a variety of cosmetic and therapeutic applications including for promoting wound healing, for reducing or preventing the formation of hypertrophic scar tissue, for reducing or preventing skin irritation and inflammation, for increasing skin's moisture and/or for reducing or preventing skin's signs of aging.

1 . A topical water free barrier composition comprising: (i) a polyamine; (ii) a phospholipid to encapsulate the primary polyamine; (iii) petroleum jelly; and (iv) mineral oil. 
     
     
         2 . The barrier composition of  claim 1 , wherein the polyamine is a primary aliphatic lower-alkyl (C1-5) monoamine, preferably aminoacetonitrile; a primary aliphatic alkylamine, preferably spermine or spermidine; or a primary aliphatic lower-alkyl (C1-5) polyamine, preferably putrescine or dansylcadaverine. 
     
     
         3 . The barrier composition of  claim 1 , wherein the polyamine is aminoacetonitrile; spermine or spermidine; or putrescine or dansylcadaverine, preferably putrescine. 
     
     
         4 . The barrier composition of  claim 3 , wherein the putrescine is in a concentration of between about 0.1% w/w to about 1% w/w; about 0.4% w/w; or about 0.8% w/w. 
     
     
         5 . The barrier composition of  claim 1 , wherein the petroleum jelly is in a concentration of between about 25% w/w and 65% w/w; or about 45% w/w. 
     
     
         6 . The barrier composition of  claim 1 , wherein the mineral oil is in a concentration of between about 30% w/w and about 45% w/w; or of about 35% w/w. 
     
     
         7 . The barrier composition of  claim 1 , wherein the phospholipid is a quaternary ammonium salt. 
     
     
         8 . The barrier composition of  claim 7 , wherein the quaternary ammonium salt is cocamidopropyl PG-dimonium chloride phosphate. 
     
     
         9 . The barrier composition of  claim 8 , wherein the cocamidopropyl PG-dimonium chloride phosphate is in a concentration of between about 3% w/w and about 6% w/w; or about 4% w/w. 
     
     
         10 . The barrier composition of  claim 1 , further comprising (i) paraffin; (ii) lanolin oil; (iii) a lipophilic Vitamin C derivative; (iv) one or more humectants; and/or (v) bisabolol. 
     
     
         11 . The barrier composition of  claim 10 , wherein the paraffin is in a concentration of between about 3% w/w and 15% w/w; or about 8.5% w/w. 
     
     
         12 . The barrier composition of  claim 10 , wherein the lanolin oil is in a concentration of between about 3% w/w and 6% w/w; or about 5% w/w. 
     
     
         13 . The composition of  claim 10 , wherein the lipophilic Vitamin C derivative is in a concentration of between about 0.1% w/w and 10% w/w. 
     
     
         14 . The composition of  claim 10 , wherein the lipophilic Vitamin C derivative comprises 3-O-Ethyl Ascorbic Acid (3-O-EAA). 
     
     
         15 . The composition of  claim 14 , wherein the 3-O-EAA is in a concentration of about 0.5% w/w. 
     
     
         16 . The barrier composition of  claim 10 , wherein the one or more humectants is(are) in a concentration of between about 0.5% w/w and 3% w/w. 
     
     
         17 . The barrier composition of  claim 10 , wherein the one or more humectants comprise(s) glycerin, vitamin B5 or a combination thereof. 
     
     
         18 . The barrier composition of  claim 17 , wherein the one or more humectants comprise(s) about 1% w/w of the glycerin and about 1% w/w of the Vitamin B5. 
     
     
         19 . The barrier composition of  claim 10 , wherein the bisabolol is in a concentration of between about 0.1% w/w and 1% w/w; or about 0.5% w/w. 
     
     
         20 . A method of using the barrier composition defined in  claim 1 , for (i) treating or preventing skin inflammation, skin's signs of aging and/or skin irritation; (ii) promoting wound healing; or (iii) preventing or reducing the formation of hypertrophic scar tissue.